相似文献
1
Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis.
Int J Environ Res Public Health. 2019 Dec 27;17(1):210. doi: 10.3390/ijerph17010210.
2
Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
Ann Pharmacother. 2020 May;54(5):457-463. doi: 10.1177/1060028019888855. Epub 2019 Nov 15.
3
Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
Tuberculosis (Edinb). 2018 Jul;111:121-126. doi: 10.1016/j.tube.2018.05.013. Epub 2018 Jun 7.
4
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Clin Infect Dis. 2015 Aug 15;61(4):527-35. doi: 10.1093/cid/civ323. Epub 2015 Apr 22.
5
Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events.
J Microbiol Immunol Infect. 2019 Feb;52(1):158-162. doi: 10.1016/j.jmii.2018.05.003. Epub 2018 Jun 2.
6
High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.
Clin Infect Dis. 2017 Oct 1;65(7):1085-1093. doi: 10.1093/cid/cix505.
7
Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
Medicine (Baltimore). 2016 Aug;95(34):e4126. doi: 10.1097/MD.0000000000004126.
8
One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial.
Clin Microbiol Infect. 2024 Nov;30(11):1410-1417. doi: 10.1016/j.cmi.2024.06.024. Epub 2024 Jul 10.
9
Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis.
J Chin Med Assoc. 2021 Nov 1;84(11):993-1000. doi: 10.1097/JCMA.0000000000000605.
10
High rate of completion for weekly rifapentine plus isoniazid treatment in Chinese children with latent tuberculosis infection-A single center study.
PLoS One. 2021 Jun 11;16(6):e0253159. doi: 10.1371/journal.pone.0253159. eCollection 2021.
引用本文的文献
1
Overlapping of DRESS and Stevens-Johnson syndrome due to first-line antituberculosis drugs: a case report.
Ther Adv Drug Saf. 2025 Jan 24;16:20420986241312484. doi: 10.1177/20420986241312484. eCollection 2025.
2
DRESS syndrome and tuberculosis: Implementation of a desensitization and re-desensitization protocol to recover antituberculosis drugs in a case series at a specialized TB Unit in Lima, Peru.
Medicine (Baltimore). 2024 Sep 27;103(39):e39365. doi: 10.1097/MD.0000000000039365.
3
Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships.
Front Pharmacol. 2024 Mar 22;15:1332752. doi: 10.3389/fphar.2024.1332752. eCollection 2024.
4
Uptake and Completion of Tuberculosis Preventive Treatment Using 12-Dose, Weekly Isoniazid-Rifapentine Regimen in Bangladesh: A Community-Based Implementation Study.
Trop Med Infect Dis. 2023 Dec 20;9(1):4. doi: 10.3390/tropicalmed9010004.
5
Next-Generation Sequencing and Bioinformatics-Based Protocol for the Full-Length Gene Polymorphism Analysis.
Pharmgenomics Pers Med. 2022 Nov 8;15:959-965. doi: 10.2147/PGPM.S371709. eCollection 2022.
6
Whole-Blood 3-Gene Signature as a Decision Aid for Rifapentine-based Tuberculosis Preventive Therapy.
Clin Infect Dis. 2022 Sep 14;75(5):743-752. doi: 10.1093/cid/ciac003.
7
Genetic polymorphism of the drug-metabolizing enzyme Cytochrome P4502E1 (CYP2E1) in a healthy Saudi population.
Saudi Pharm J. 2021 Nov;29(11):1355-1360. doi: 10.1016/j.jsps.2021.09.013. Epub 2021 Oct 6.
8
Determinants of Drug-Induced Hepatotoxicity Among Patients with Human Immunodeficiency Virus Taking a High Dose of Rifapentine Plus Isoniazid Drugs at the All Africa Leprosy Tuberculosis Rehabilitation and Training Center in Addis Ababa, Ethiopia.
HIV AIDS (Auckl). 2021 Mar 16;13:307-314. doi: 10.2147/HIV.S300135. eCollection 2021.
9
Role of Militarine in PM-Induced BV-2 Cell Damage.
Neurochem Res. 2021 Jun;46(6):1423-1434. doi: 10.1007/s11064-021-03281-6. Epub 2021 Mar 6.
10
Impact of Age on Outcome of Rifapentine-Based Weekly Therapy for Latent Tuberculosis Infection.
Clin Infect Dis. 2021 Sep 7;73(5):e1064-e1071. doi: 10.1093/cid/ciaa1741.
本文引用的文献
1
Impact of Long Non-Coding RNA Genetic Variants on the Susceptibility and Clinicopathologic Characteristics of Patients with Urothelial Cell Carcinoma.
J Clin Med. 2019 Feb 26;8(3):282. doi: 10.3390/jcm8030282.
2
Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
J Antimicrob Chemother. 2019 Jan 1;74(1):218-227. doi: 10.1093/jac/dky403.
3
Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine.
Clin Infect Dis. 2018 Jul 2;67(2):193-201. doi: 10.1093/cid/ciy082.
4
Isoniazid metabolism and hepatotoxicity.
Acta Pharm Sin B. 2016 Sep;6(5):384-392. doi: 10.1016/j.apsb.2016.07.014. Epub 2016 Aug 3.
5
Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
Medicine (Baltimore). 2016 Aug;95(34):e4126. doi: 10.1097/MD.0000000000004126.
6
Pharmacogenomics in the clinic.
Nature. 2015 Oct 15;526(7573):343-50. doi: 10.1038/nature15817.
7
Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.
Int J Tuberc Lung Dis. 2015 Sep;19(9):1039-44, i-v. doi: 10.5588/ijtld.14.0829.
8
Pharmacogenetics of isoniazid-induced hepatotoxicity.
Drug Metab Rev. 2015 May;47(2):222-8. doi: 10.3109/03602532.2014.984070. Epub 2014 Nov 19.
9
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
Clin Infect Dis. 2015 Oct 15;61(8):1322-7. doi: 10.1093/cid/civ464. Epub 2015 Jun 16.
10
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Clin Infect Dis. 2015 Aug 15;61(4):527-35. doi: 10.1093/cid/civ323. Epub 2015 Apr 22.
Zotero 插件